A Population of HLA-DR+ Immature Cells Accumulates in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer

View/ Open
Author(s)
Pinzon-Charry, A
Ho, CSK
Laherty, R
Maxwell, T
Walker, D
Gardiner, RA
O'Connor, L
Pyke, C
Schmidt, C
Furnival, C
Lopez, JA
Griffith University Author(s)
Year published
2005
Metadata
Show full item recordAbstract
Dendritic cell (DC) defects are an important component of immunosuppression in cancer. Here, we assessed whether cancer could affect circulating DC populations and its correlation with tumor progression. The blood DC compartment was evaluated in 136 patients with breast, prostate cancer and malignant glioma. Phenotypic, quantitative and functional analyses were performed at various stages of disease. Patients had significantly fewer circulating myeloid (CD11c+DC) and lymphoid (CD123+DC) DC, and a concurrent accumulation of CD11c-CD123- immature cells which expressed high levels of HLA-DR (DR+IC). Although DR+IC exhibited ...
View more >Dendritic cell (DC) defects are an important component of immunosuppression in cancer. Here, we assessed whether cancer could affect circulating DC populations and its correlation with tumor progression. The blood DC compartment was evaluated in 136 patients with breast, prostate cancer and malignant glioma. Phenotypic, quantitative and functional analyses were performed at various stages of disease. Patients had significantly fewer circulating myeloid (CD11c+DC) and lymphoid (CD123+DC) DC, and a concurrent accumulation of CD11c-CD123- immature cells which expressed high levels of HLA-DR (DR+IC). Although DR+IC exhibited limited expression of markers ascribed to mature hematopoietic lineages, expression of HLA-DR, CD40 and CD86 suggested a role as antigen presenting cells. Nevertheless, DR+IC had a reduced capacity to capture antigen and elicited poor proliferation and IFN-?נsecretion by T-lymphocytes. Importantly, increased numbers of DR+IC correlated with disease status. Patients with metastatic breast cancer showed a larger number of DR+IC in the circulation than patients with local/nodal disease. Similarly, in patients with fully-resected glioma, the proportion of DR+IC in blood increased when evaluation indicated tumor recurrence. The reduction of blood DC correlating with the accumulation of a population of immature cells with poor immunological function may be associated with the increased immunodeficiency observed in cancer.
View less >
View more >Dendritic cell (DC) defects are an important component of immunosuppression in cancer. Here, we assessed whether cancer could affect circulating DC populations and its correlation with tumor progression. The blood DC compartment was evaluated in 136 patients with breast, prostate cancer and malignant glioma. Phenotypic, quantitative and functional analyses were performed at various stages of disease. Patients had significantly fewer circulating myeloid (CD11c+DC) and lymphoid (CD123+DC) DC, and a concurrent accumulation of CD11c-CD123- immature cells which expressed high levels of HLA-DR (DR+IC). Although DR+IC exhibited limited expression of markers ascribed to mature hematopoietic lineages, expression of HLA-DR, CD40 and CD86 suggested a role as antigen presenting cells. Nevertheless, DR+IC had a reduced capacity to capture antigen and elicited poor proliferation and IFN-?נsecretion by T-lymphocytes. Importantly, increased numbers of DR+IC correlated with disease status. Patients with metastatic breast cancer showed a larger number of DR+IC in the circulation than patients with local/nodal disease. Similarly, in patients with fully-resected glioma, the proportion of DR+IC in blood increased when evaluation indicated tumor recurrence. The reduction of blood DC correlating with the accumulation of a population of immature cells with poor immunological function may be associated with the increased immunodeficiency observed in cancer.
View less >
Journal Title
Neoplasia
Volume
7
Issue
12
Publisher URI
Copyright Statement
© 2005 Neoplasia Press. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Subject
Clinical sciences
Immunology not elsewhere classified